| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Empasiprubart | ARGX-117 | Phase 3 Clinical | Argenx Se, Broteio Pharma BV | Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Dermatomyositis; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Myositis; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |